Lapatinib

Therapeutic Group

Anti-neoplastics

Indication Dosage

Lapatinib is indicated for the treatment of certain types of breast cancer. It is prescribed in combination with other medications for patients with HER2-positive metastatic breast cancer that has progressed after prior therapy. Lapatinib may also be used in combination with another medication for HER2-positive early-stage breast cancer after surgery. 

Treatment Of Advanced Or Metastatic Breast Cancer In Patients With Tumours That Over Express Human Epidermal Growth Factor Receptor-2 (her2) With Hormone-receptor-negative Disease (in Combination With Trastuzumab): 

  • Adult: 1 G Once Daily, Or In Combination With Capecitabine,1.25 G Once Daily, Or For Postmenopausal Women, In Combination With An Aromatase Inhibitor, 1.5 G Once Daily. Counseling: Always Take At The Same Time, Either 1 hour before Or 1 hour after Food.

Content

  • Tab: Lapatinib 250mg.

Pregnancy

Positive Evidence Of Risk: Avoid

Stability

  • Protein Kinase Inhibitor

Contra Indications

  • Hypersensitivity.

Precautions

  • Hypersensitivity.

Lactation

  • Contraindicated. Discontinue Breast-feeding

Side Effects

  • Anorexia
  • Cardiac Failure (fatal Cases Reported)
  • Decreased Left Ventricular Ejection Fraction
  • Diarrhoea (treat Promptly)
  • Hepatotoxicity (discontinue Permanently If Severe)
  • Hyperbilirubinaemia
  • Malaise
  • Nail Disorders
  • Rash
  • Interstitial Lung Disease
  • Alopecia
  • Bone-marrow Suppression
  • Hyperuricaemia
  • Nausea
  • Oral Mucositis
  • Respiratory Failure (including Fatal Cases)
  • Thromboembolism
  • Tumourlysis Syndrome
  • Vomiting

Available Brands